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Background: Acinetobacter baumannii is a major health problem. The most common infection caused by A. baumannii
is hospital acquired pneumonia, and the associated mortality rate is approximately 50 %. Neither in vivo nor ex vivo
expression profiling has been performed at the proteomic or transcriptomic level for pneumonia caused by A. baumannii.
In this study, we characterized the proteome of A. baumannii under conditions that simulate those found in the airways,
to gain some insight into how A. baumannii adapts to the host and to improve knowledge about the pathogenesis and
virulence of this bacterium. A clinical strain of A. baumannii was grown under different conditions: in the presence of
bronchoalveolar lavage fluid from infected rats, of RAW 264.7 cells to simulate conditions in the respiratory tract and in
control conditions. We used iTRAQ labelling and LC-MALDI-TOF/TOF to investigate how A. baumannii responds
on exposure to macrophages/BALF.
Results: 179 proteins showed differential expression. In both models, proteins involved in the following processes
were over-expressed: (i) pathogenesis and virulence (OmpA, YjjK); (ii) cell wall/membrane/envelope biogenesis (MurC);
(iii) energy production and conversion (acetyl-CoA hydrolase); and (iv) translation (50S ribosomal protein L9). Proteins
involved in the following were under-expressed: (i) lipid metabolism (short-chain dehydrogenase); (ii) amino
acid metabolism and transport (aspartate aminotransferase); (iii) unknown function (DNA-binding protein); and
(iv) inorganic ion transport and metabolism (hydroperoxidase).
Conclusions: We observed alterations in cell wall synthesis and identified 2 upregulated virulence-associated
proteins with >15 peptides/protein in both ex vivo models (OmpA and YjjK), suggesting that these proteins are
fundamental for pathogenesis and virulence in the airways. This study is the first comprehensive overview of
the ex vivo proteome of A. baumannii and is an important step towards identification of diagnostic biomarkers,
novel drug targets and potential vaccine candidates in the fight against pneumonia caused by A. baumannii.
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The World Health Organization has recently identified
antimicrobial resistance as one of the three most
important problems facing human health. The most
common and serious multidrug-resistant pathogens
have been encompassed within the acronym “ESKAPE”,
which stands for Enterococcus faecium, Staphylococcus* Correspondence: German.Bou.Arevalo@sergas.es
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unless otherwise stated.aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa and Enterobacter spp. [1].
Acinetobacter baumannii is an important opportunistic
nosocomial pathogen that is often associated with epi-
demic outbreaks of infection. This organism is frequently
pandrug-resistant and is capable of causing substantial
morbidity and mortality in patients with severe underlying
disease, both in the hospital and in the community [2].
Acinetobacter baumannii is an uncommon but important
cause of community-acquired pneumonia, which appears
to be a unique clinical entity occurring predominantly inl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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appears to be characterized by a fulminant course, with
acute onset of dyspnea, cough and fever followed by
rapid progression to respiratory failure and shock. The
mortality rate is high (40–64 %) [3, 4]. Nosocomial
pneumonia is the most important infection caused by
A. baumannii and is particularly associated with the
application of mechanical ventilatory procedures [5].
The crude mortality rate associated with nosocomial
Acinetobacter infections has been reported to range
from 20 to 45 % [6, 7]. A prospective study of 240 A.
baumannii infections showed that > 90 % of infections
were nosocomially acquired and that only 4 % were com-
munity acquired; moreover, respiratory track infections
were the most common (39.3 %) [8]. Acinetobacter
baumannii has a propensity to cause outbreaks, probably
because of its ability to survive desiccation and its multi-
drug resistance, amongst other reasons [9]. Although A.
baumannii is only rarely isolated from soil, vegetables,
animals, humans and inanimate surfaces that are often in
contact with humans [10], the natural habitats of A.
baumannii remain to be established [11]. In the
community, A. baumannii is a rare colonizer of human
skin in temperate climates, although skin carriage is
more common in tropical environments [12, 13]. In
Australia, wet-season throat carriage of A. baumannii
was found in 10 % of community residents with excess
levels of alcohol consumption [3]. The bacterium is
ubiquitous in the hospital setting (e.g., bedside, bedrail,
ventilator, infusion pump, pillow, resuscitation equip-
ment, washbasins) [14, 15]. Furthermore, A. baumannii
is found to persist as a contaminant of the hands,
gloves and gowns of healthcare workers [16, 17]. This
bacterium can survive on inanimate objects for long
periods, even after exposure to dry conditions [18] and
is also capable of resisting physical and chemical disinfec-
tion, often by forming a biofilm [19]. It has a remarkable
ability to up-regulate or acquire resistance determinants,
making it one of the most important microorganisms
threatening the current antibiotic era [11]. Numerous out-
breaks of pandrug-resistant A. baumannii have been
documented in Asian and Middle East hospitals. Resist-
ance to both tigecycline and polymyxin B (drugs relied on
heavily to treat infection with A. baumannii) already exists
in these regions [20, 21].
The first genome of an Acinetobacter spp. to be
sequenced was that of the highly transformable Acineto-
bacter spp. strain ADP1 in 2004 [22]. The first com-
pleted A. baumannii genome was reported for strain
ATCC 17978 in 2007 and included a considerable
number of the island-containing genes (16) implicated
in virulence, indicating that several of the microorgan-
ism’s genes are devoted to pathogenesis. The largest
island contains elements homologous to the Legionella/Coxiella Type IV secretion apparatus. Type IV secretion
systems have been demonstrated to be important for
virulence in other microorganisms and are thus likely
to help mediate the pathogenesis of A. baumannii [23].
Several extracellular proteins of A. baumannii, grown
in vitro, have been identified by the use of different
proteomic approaches [24, 25]. Such approaches have
been used for membrane and cytoplasmic proteomic
analysis of A. baumannii grown in vitro [26–30]. Com-
parative proteomic analysis has been performed with
cells at three different stages of in vitro growth: expo-
nential, late stationary phase and as biofilms [31]. Com-
parative proteomic analysis of a multidrug resistant
strain with a drug-sensitive strain has also been per-
formed [32]. In vitro culture conditions may stress bac-
teria (e.g. due to exhaustion of static nutrients, build-up
of toxic bacterial by-products and limited physical
space). However, simulated in vitro environments do
not accurately reflect the protein profile within the
lung, because A. baumannii must adjust to the environ-
ment inside the host lung (e.g., CO2 concentrations,
temperature and immune system) to be able to cause
pneumonia.
The goal of this study was to improve our knowledge of
the pathogenesis and virulence of A. baumannii by con-
sidering how the bacterium adapts to its host. In order to
obtain an overview of host-pathogen-interactions during
A. baumannii infections, we used, for the first time, a
proteomics approach to compare the ex vivo proteomes of
A. baumannii grown under different that mimic the
physiological conditions that bacteria must face during
in vivo host infection.
Results
The objective of this study was to improve our know-
ledge of the pathogenesis and virulence of A. baumannii
and to investigate how this bacterium adapts to its host.
For this purpose, A. baumannii cells were cultured in
LB (Luria-Bertani) medium with or without BALF
(BALF model) and in Dulbecco’s Modified Eagle’s
Medium (DMEM) medium with or without RAW
264.7 cells (macrophage model). The proteome com-
position of the A. baumannii cells in both models was
analyzed in parallel, by using iTRAQ labelling and LC-
MALDI-TOF/TOF to investigate the response of A.
baumannii to exposure to macrophages/BALF (according
to the scheme shown in Additional file 1).
Acinetobacter baumannii caused consolidated pneumonia
BALF contains lipids, nucleic acids, secretomes of macro-
phages, lymphocytes, neutrophils, eosinophils, epithelial
cells, pneumocytes, monocytes and basophils. Moreover,
infection is capable of causing changes in concentrations,
ratios and numbers of proteins detected in BALF.
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tract in response to A. baumannii infection, rats were
inoculated with the bacterium and BALFs were
obtained 21 h later. For histological assessment of A.
baumannii infection of the airway, lung specimens
were stained with haematoxylin and eosin and exam-
ined microscopically. Abscess formation, with exten-
sive infiltration of polymorphonuclear leukocytes was
noted [see Additional file 2].
Quantitative (iTRAQ) data analysis
In the BALF model, A. baumannii was incubated simul-
taneously in LB and in LB supplemented with BALF
(containing host soluble components present inside the
lung 21 h after inoculation with A. baumannii) for 21 h
at 37 °C and 5 % CO2 without shaking, in order to study
the A. baumannii responses to soluble BALF compo-
nents at the protein level by iTRAQ labelling and LC-
MALDI/TOF analysis. Changes in the proteome of A.
baumannii in response to soluble BALF components
were examined. The rate of false positive results was es-
timated to be less than 1 % (with a confidence interval
of 95 %) as the search was conducted in parallel with a
decoy database using the “PSPEP on” mode, suggesting a
high degree of confidence in the reported protein identi-
fications. To evaluate the reproducibility and effective-
ness of the iTRAQ experiments, we compared the
proteins identified in each iTRAQ set. Overall, 8,310
unique peptides and 896 distinct proteins were detected
with more than 95 % confidence in both iTRAQ sets. In
biological replicate one, 730 proteins were identified and
in biological replicate two, 853 proteins were identified.
Only about 15.7 % of the proteins were identified with a
single peptide. In total, 687 proteins (76.7 %) were iden-
tified in both biological replicates, and only 209 proteins
(23.3 %) were unique for a single iTRAQ experiment.
These results indicate the reliability of the iTRAQ iden-
tification of 687 proteins in all data sets. Compared
with the control group, 111 identified proteins dis-
played significant changes in expression. In total, 50
proteins tended to be over-expressed (fold change >1.5,
p <0.05) and 61 proteins tended to be under-expressed
(fold change <0.5, p <0.05) relative to the control group
(Table 1).
In the macrophage model, infection of macrophages
was induced with A. baumannii (multiplicity of infec-
tion 3). Control and infected cells were incubated sim-
ultaneously for 21 h at 37 °C and 5 % CO2, without
shaking, in order to study the A. baumannii responses
to immune system cells at the protein level by iTRAQ
labelling and LC-MALDI/TOF analysis. Changes in
the proteome of A. baumannii in response to RAW
264.7 cells were also examined. In comparison with
the control group, 97 identified proteins displayedsignificant changes in expression. A total of 76 proteins
displayed increased expression levels (fold change >1.5,
p <0.05) and 21 proteins displayed decreased expres-
sion levels (fold change <0.5, p <0.05) relative to the
control group (Table 2).
Overall, 179 differentially expressed proteins were
identified in both models. 111 proteins were modulated
in the BALF model and 97 proteins were modulated in
the macrophage model. In the BALF model, 45.0 % of
the differentially expressed proteins were over-expressed.
In the macrophage model, 78.4 % of the modulated pro-
teins were over-expressed. Of the 179 modulated pro-
teins, 16.2 % (29 proteins) were differentially expressed
in both models, 51.7 % (15 proteins) were overexpressed,
20.7 % (6 proteins) were underexpressed and 27.6 % (8
proteins) were opposite (over-expressed in a model and
under-expressed in the other model) (Fig. 1, Table 3).Analysis of modulated proteins
According to their predicted biological functions, the
differentially expressed proteins were divided into 19
groups (Fig. 2). The largest groups consisted of proteins
involved in translation (58), followed by the proteins in-
volved in energy production and conversion (27) and by
proteins involved in pathogenesis and virulence (23).
Most of the proteins over-expressed in the BALF model
were involved in translation (38.0 %), followed by patho-
genesis and virulence (14.0 %), and energy production
and conversion (10.0 %). In the macrophage model, most
were involved in translation (40.8 %), followed by energy
production and conversion (13.2 %), and pathogenesis
and virulence (10.5 %). Most of the proteins that were
under-expressed in the BALF model were involved in
energy production and conversion (19.7 %) and in the
macrophage model most were proteins of unknown
function (28.6 %).
Of the 29 proteins differentially expressed in both
models, most were involved in translation (37.9 %),
followed by pathogenesis and virulence (17.2 %) and by
unknown function (10.3 %). Most of the over-expressed
proteins were involved in translation, whereas most of
the under-expressed proteins were proteins of unknown
function, and 50.0 % of opposite proteins were associ-
ated with metabolism (Table 3).RT-PCR
We selected some proteins for validation of the proteomic
data by RT-PCR analysis. The candidate proteins, NfuA-
like, YjjK, CsuC, OmpW, OmpA, ClpX, DNA repair, PaaA
and PpiA were selected on the basis of their differential
expression as representative of pathogenesis and viru-
lence, cell wall/membrane/envelope biogenesis and other
functional categories.
Table 1 Differentially expressed proteins under ex vivo conditions in BALF model
Protein description AbH12O-A2 locus Sec.a BALF model/controlb BALF model/control p-valuec
Pathogenesis and virulence
Molecular chaperone DnaK AIS05048.1 NO 1.77 (0.65) 0.027
Clp protease ClpX AIS05265.1 NO 1.51 (0.61) 0.024
Amino acid ABC transporter substrate-binding protein (NfuA-like) AIS05727.1 YES 2.38 (1.76) 0.031
Enoyl-CoA hydratase (PaaZ) AIS06043.1 NO 0.30 (0.11) 0.012
Peptidase M16 AIS06751.1 NO 0.29 (0.16) 0.007
Aminopeptidase N AIS06953.1 NO 0.39 (0.21) 0.023
Protein CsuC AIS07073.1 YES 2.19 (0.76) 0.003
Protein CsuA AIS07075.1 YES 1.87 (0.95) 0.036
Membrane protein (OmpA) AIS07737.1 YES 1.51 (0.65) 0.015
Oligopeptidase A AIS07885.1 NO 0.48 (0.11) 0.001
ABC transporter ATP-binding protein (YjjK) AIS08062.1 NO 1.74 (0.61) 0.038
Amino acid metabolism and transport
Aspartate-semialdehyde dehydrogenase AIS05215.1 NO 0.25 (0.19) 0.038
2-Isopropylmalate synthase AIS05260.1 NO 0.31 (0.11) 0.034
Ketol-acid reductoisomerase AIS05310.1 NO 0.31 (0.05) 0.027
Ornithine carbamoyltransferase AIS06867.1 NO 0.40 (0.17) 0.044
Aspartate aminotransferase AIS07065.1 NO 0.08 (0.07) 0.000
Glutamate synthase AIS08029.1 NO 0.39 (0.20) 0.025
Carbohydrate metabolism and transport
Phosphoglyceromutase AIS05033.1 NO 0.26 (0.14) 0.020
Phosphoenolpyruvate synthase AIS07024.1 NO 0.19 (0.04) 0.000
Glucose dehydrogenase AIS07744.1 NO 0.19 (0.13) 0.009
Cell cycle control and mitosis
Cell division inhibitor MinD AIS05622.1 NO 1.63 (1.55) 0.000
tRNA uridine 5-carboxymethylaminomethyl modification protein AIS07041.1 NO 2.70 (1.89) 0.025
Cell division protein FtsZ AIS08195.1 NO 4.61 (1.68) 0.001
Cell wall/membrane/envelope biogenesis
Membrane protein(OmpW) AIS05087.1 YES 2.25 (0.89) 0.032
UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA) AIS05387.1 NO 2.27 (1.47) 0.002
UDP-N-acetylmuramate-alanine ligase (MurC) AIS08199.1 NO 99.08 (0.00) 0.020
Coenzyme metabolism
Coproporphyrinogen III oxidase AIS07950.1 NO 0.31 (0.13) 0.004
3-Phosphoglycerate dehydrogenase AIS07996.1 NO 0.38 (0.09) 0.016
Defense mechanisms (cellular processes and signaling)
RND transporter AIS04803.1 YES 0.30 (0.22) 0.004
Energy production and conversion
Malate dehydrogenase AIS04961.1 NO 0.45 (0.23) 0.038
Inorganic pyrophosphatase AIS05013.1 YES 2.83 (1.43) 0.030
Aconitate hydratase AIS05319.1 NO 0.21 (0.16) 0.000
NAD(P) transhydrogenase subunit alpha AIS05328.1 NO 2.49 (1.37) 0.041
NADH dehydrogenase AIS05456.1 NO 0.44 (0.17) 0.012
Cytochrome C oxidase subunit II AIS07026.1 NO 0.21 (0.23) 0.016
Malic enzyme AIS07199.1 NO 0.46 (0.10) 0.041
Isocitrate dehydrogenase AIS07371.1 NO 0.29 (0.05) 0.004
Phosphoenolpyruvate carboxykinase AIS07529.1 NO 2.23 (0.66) 0.000
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Table 1 Differentially expressed proteins under ex vivo conditions in BALF model (Continued)
Succinyl-CoA synthetase subunit beta AIS07559.1 NO 0.41 (0.06) 0.035
Energy production and conversion
2-Oxoglutarate dehydrogenase AIS07562.1 NO 0.20 (0.04) 0.000
Succinate dehydrogenase AIS07563.1 NO 1.98 (0.64) 0.017
Type II citrate synthase AIS07567.1 NO 0.22 (0.05) 0.002
Oxidoreductase AIS07724.1 NO 0.31 (0.22) 0.001
Malate dehydrogenase AIS07865.1 NO 0.47 (0.06) 0.040
Acetyl-CoA hydrolase AIS08069.1 NO 2.05 (0.67) 0.008
Pyruvate dehydrogenase AIS08191.1 NO 0.36 (0.06) 0.000
Unknown function
Hypothetical protein AIS05481.1 YES 0.07 (0.10) 0.013
Peptidoglycan-binding protein LysM AIS05521.1 YES 0.05 (0.03) 0.003
Hypothetical protein AIS06125.1 YES 0.17 (0.07) 0.027
DNA-binding protein AIS07086.1 YES 0.08 (0.07) 0.006
Peptidase AIS07285.1 YES 4.57 (3.14) 0.000
Glyoxalase AIS07740.1 YES 0.39 (0.45) 0.015
Hypothetical protein AIS07742.1 YES 1.84 (1.06) 0.048
General functional prediction only (typically, prediction of biochemical activity)
Alpha/beta hydrolase AIS06658.1 YES 0.09 (0.07) 0.001
GTPase obg AIS07390.1 NO 2.58 (1.05) 0.025
Hypothetical protein AIS07569.1 NO 3.47 (1.83) 0.027
Inorganic ion transport and metabolism
Bacterioferritin AIS05502.1 NO 0.25 (0.18) 0.013
Hydroperoxidase AIS06129.1 YES 0.26 (0.10) 0.000
Inorganic ion transport and metabolism
Superoxide dismutase AIS07203.1 YES 0.49 (0.14) 0.013
Sulfurtransferase AIS07821.1 NO 0.37 (0.28) 0.006
Intracellular trafficking and secretion
RNA-binding protein AIS05494.1 NO 2.07 (0.97) 0.001
Lipid metabolism
3-Ketoacyl-CoA thiolase AIS05097.1 NO 0.35 (0.18) 0.049
Multifunctional fatty acid oxidation complex subunit alpha AIS05098.1 NO 0.29 (0.08) 0.000
Acetyl-CoA carboxylase AIS05368.1 NO 2.01 (0.67) 0.000
3-Hydroxyacyl-CoA dehydrogenase AIS06051.1 NO 0.32 (0.22) 0.023
Beta-ketoadipyl CoA thiolase AIS06052.1 NO 0.28 (0.10) 0.000
3-Methylcrotonyl-CoA carboxylase AIS06111.1 NO 0.11 (0.04) 0.002
Short-chain dehydrogenase AIS06130.1 YES 0.04 (0.05) 0.040
Acetyl-CoA acetyltransferase AIS06469.1 YES 0.09 (0.13) 0.027
Acetyl-CoA carboxylase AIS06900.1 NO 0.42 (0.17) 0.001
3-Hydroxy-2-methylbutyryl-CoA dehydrogenase AIS07009.1 NO 0.25 (0.18) 0.031
Acetyl-CoA acetyltransferase AIS07739.1 YES 0.24 (0.26) 0.017
Acyl-CoA dehydrogenase AIS07780.1 NO 0.22 (0.16) 0.000
Nucleotide metabolism and transport
GMP synthase AIS04952.1 NO 0.31 (0.17) 0.000
Formyltetrahydrofolate deformylase AIS05238.1 NO 1.64 (1.02) 0.012
Deoxyuridine 5′-triphosphate nucleotidohydrolase AIS05628.1 NO 4.45 (6.37) 0.039
Dihydroorotase AIS05812.1 NO 1.79 (1.15) 0.043
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Table 1 Differentially expressed proteins under ex vivo conditions in BALF model (Continued)
Nucleotide metabolism and transport
Orotate phosphoribosyltransferase AIS08207.1 NO 2.73 (1.78) 0.004
Post-translational modification, protein turnover, chaperone functions
Peroxidase AIS07758.1 YES 0.25 (0.21) 0.033
Replication and repair
Chromosomal replication initiation protein AIS04811.1 NO 81.66 (31.26) 0.017
DNA gyrase subunit A AIS07481.1 NO 0.09 (0.16) 0.004
Transcription
Antitermination protein NusG AIS05075.1 NO 2.00 (0.81) 0.010
DNA-directed RNA polymerase subunit beta AIS05080.1 NO 0.26 (0.05) 0.000
DNA-directed RNA polymerase subunit beta’ AIS05081.1 NO 0.10 (0.04) 0.000
RNA polymerase sigma factor RpoD AIS07572.1 NO 1.92 (1.40) 0.042
Translation
Isoleucine-tRNA ligase AIS04850.1 NO 0.28 (0.09) 0.001
Arginine-tRNA ligase AIS04960.1 NO 0.47 (0.16) 0.019
50S ribosomal protein L1 AIS05077.1 YES 3.40 (0.93) 0.000
30S ribosomal protein S15 AIS05149.1 NO 15.56 (6.87) 0.045
50S ribosomal protein L28 AIS05235.1 YES 1.85 (0.68) 0.042
Leucyl-tRNA synthetase AIS05306.1 NO 0.39 (0.16) 0.029
Threonyl-tRNA synthetase AIS05352.1 NO 0.09 (0.16) 0.000
30S ribosomal protein S7 AIS05609.1 NO 9.91 (4.58) 0.000
Elongation factor Tu AIS05611.1 NO 0.34 (0.05) 0.002
Cysteinyl-tRNA synthetase AIS05938.1 NO 0.18 (0.11) 0.015
30S ribosomal protein S6 AIS07031.1 NO 3.56 (0.80) 0.004
Translation
50S ribosomal protein L9 AIS07033.1 NO 4.70 (2.06) 0.000
30S ribosomal protein S21 AIS07108.1 YES 4.33 (3.26) 0.040
50S ribosomal protein L21 AIS07586.1 NO 4.45 (2.38) 0.029
Valyl-tRNA synthetase AIS07599.1 NO 0.17 (0.14) 0.000
30S ribosomal protein S9 AIS07845.1 YES 6.19 (2.19) 0.005
50S ribosomal protein L17 AIS07895.1 YES 15.14 (7.44) 0.025
30S ribosomal protein S11 AIS07898.1 YES 3.40 (1.58) 0.002
50S ribosomal protein L15 AIS07902.1 NO 5.06 (1.54) 0.000
50S ribosomal protein L6 AIS07906.1 YES 5.35 (2.12) 0.000
30S ribosomal protein S8 AIS07907.1 YES 7.52 (1.56) 0.007
50S ribosomal protein L5 AIS07909.1 NO 7.18 (2.38) 0.000
50S ribosomal protein L14 AIS07911.1 NO 5.20 (1.87) 0.002
50S ribosomal protein L22 AIS07916.1 NO 2.03 (0.76) 0.012
50S ribosomal protein L23 AIS07919.1 YES 1.77 (0.58) 0.043
Aminoglycoside phosphotransferase AIS08113.1 NO 2.88 (4.81) 0.015
The protein profiles produced by A. baumannii grown in modified BALF were performed using iTRAQ reagents and LC-MS/MS. Differential expression was
defined by a relative abundance ratio >1.5 and <0.5
aSecretion prediction are based on (SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/), Phobius (http://phobius.sbc.su.se/), PrediSi (http://www.predisi.de/),
TatP 1.0 (www.cbs.dtu.dk/services/TatP-1.0), Tatfind 1.4 (http://signalfind.org/tatfind.html), SecretomeP 2.0 (www.cbs.dtu.dk/services/SecretomeP), TMHMM
(http://www.cbs.dtu.dk/services/TMHMM/), DAS-TMfilter (http://www.enzim.hu/DAS/DAS.html), LipoP 1.0 (www.cbs.dtu.dk/services/LipoP), DOLOP (http://
www.mrc-lmb.cam.ac.uk/genomes/dolop/), and LIPO (http://services.cbu.uib.no/tools/lipo))
bAverage relative protein expression level ratio in sample and control, with the standard deviation in parentheses, quantified by Protein Pilot 4.0 software (ABSciex).
cDetermined by Student’s t test. Values of less than 0.05 are considered significant
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Table 2 Differentially expressed proteins under ex vivo conditions in macrophage model





Nucleotidyl transferase AIS04894.1 NO 2.83 (0.60) 0.013
Trigger factor AIS05263.1 NO 3.37 (0.37) 0.016
ATPase AAA (PaaA) AIS06044.1 NO 5.50 (4.44) 0.028
Siderophore achromobactin biosynthesis proteína AcsC AIS06377.1 NO 0.44 (0.17) 0.000
Cyclophilin (PPIase) AIS06968.1 NO 2.83 (0.87) 0.041
Protein CsuC AIS07073.1 YES 0.16 (0.06) 0.004
Protein CsuA AIS07075.1 YES 0.31 (0.22) 0.040
Metallopeptidase AIS07555.1 YES 0.20 (0.16) 0.028
Membrane protein (OmpA) AIS07737.1 YES 7.80 (2.78) 0.049
Oligopeptidase A AIS07885.1 NO 4.83 (0.88) 0.006
ABC transporter ATP-binding protein (YjjK) AIS08062.1 NO 2.33 (0.77) 0.046
Amino acid metabolism and transport
Aspartate aminotransferase AIS07065.1 NO 0.39 (0.18) 0.010
Serine hydroxymethyltransferase AIS07167.1 NO 2.54 (0.44) 0.043
Carbamoyl-phosphate synthase AIS07544.1 NO 2.75 (1.74) 0.035
4-Hydroxyphenylpyruvate dioxygenase AIS08279.1 NO 4.74 (1.15) 0.000
Carbohydrate metabolism and transport
Phosphoglyceromutase AIS05033.1 NO 3.94 (1.06) 0.032
Glyceraldehyde-3-phosphate dehydrogenase AIS07393.1 NO 3.08 (0.66) 0.016
Cell cycle control and mitosis
Cell division protein FtsA AIS08196.1 NO 4.74 (7.32) 0.002
Cell wall/membrane/envelope biogenesis
Membrane protein AIS06856.1 YES 8.02 (7.90) 0.006
Racemase AIS07059.1 NO 0.20 (0.13) 0.037
UDP-N-acetylmuramate-alanine ligase (MurC) AIS08199.1 NO 8.17 (3.95) 0.040
Coenzyme metabolism
Pantoate-beta-alanine ligase (PanC) AIS05347.1 NO 6.08 (8.59) 0.010
3-Phosphoglycerate dehydrogenase AIS07996.1 NO 3.77 (0.88) 0.014
Defense mechanisms (cellular processes and signaling)
Beta-lactamase AIS07280.1 YES 2.09 (0.41) 0.049
ABC transporter AIS07290.1 NO 0.39 (0.18) 0.037
Energy production and conversion
ATP synthase subunit B AIS04971.1 NO 5.50 (2.54) 0.044
ATP synthase F0F1 subunit beta AIS04975.1 NO 3.63 (0.48) 0.002
Bifunctional aconitate hydratase 2/2-methylisocitrate dehydratase AIS06989.1 NO 3.16 (0.31) 0.002
Isocitrate dehydrogenase AIS07371.1 NO 4.57 (0.55) 0.002
Electron transfer flavoprotein subunit beta AIS07482.1 YES 5.65 (0.89) 0.005
Dihydrolipoamide succinyltransferase AIS07561.1 NO 2.44 (0.45) 0.036
Fumarate reductase AIS07564.1 NO 3.08 (0.59) 0.010
Acetyl-CoA hydrolase AIS08069.1 NO 4.74 (1.68) 0.040
NADPH:quinone oxidoreductase AIS08156.1 NO 15.42 (16.20) 0.034
Dihydrolipoamide acetyltransferase AIS08190.1 YES 3.08 (0.73) 0.010
Unknown function
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Table 2 Differentially expressed proteins under ex vivo conditions in macrophage model (Continued)
Hypothetical protein AIS05430.1 NO 19.23 (19.19) 0.001
Hypothetical protein AIS05481.1 YES 0.17 (0.08) 0.000
Unknown function
Hypothetical protein AIS05936.1 YES 0.23 (0.13) 0.006
DNA-binding protein AIS07086.1 YES 0.24 (0.17) 0.037
Hypothetical protein AIS07091.1 NO 0.21 (0.12) 0.000
DcaP-like protein AIS07608.1 YES 11.07 (6.85) 0.023
Glyoxalase AIS07740.1 YES 0.30 (0.23) 0.036
Hypothetical protein AIS07873.1 YES 0.42 (0.16) 0.011
Inorganic ion transport and metabolism
Hydroperoxidase AIS06129.1 YES 0.35 (0.13) 0.008
ABC transporter permease AIS07421.1 YES 8.17 (3.60) 0.034
Lipid metabolism
3-Oxoacyl-ACP reductase AIS05519.1 YES 2.68 (0.94) 0.038
Enoyl-CoA hydratase AIS06112.1 NO 0.17 (0.24) 0.004
Short-chain dehydrogenase AIS06130.1 YES 0.10 (0.07) 0.032
Nucleotide metabolism and transport
N5-carboxyaminoimidazole ribonucleotide mutase AIS04832.1 NO 4.02 (2.98) 0.010
Ribose-phosphate pyrophosphokinase AIS05530.1 NO 4.61 (2.76) 0.000
Deoxyuridine 5′-triphosphate nucleotidohydrolase AIS05628.1 NO 0.28 (0.32) 0.032
Orotidine 5′-phosphate decarboxylase AIS06325.1 NO 0.19 (0.21) 0.032
Adenylosuccinate lyase AIS07333.1 NO 6.31 (2.68) 0.047
Xanthine phosphoribosyltransferase AIS07874.1 NO 2.42 (0.69) 0.048
Inosine-5-monophosphate dehydrogenase AIS08184.1 NO 3.94 (0.81) 0.006
Post-translational modification, protein turnover, chaperone functions
Molecular chaperone DnaK AIS04838.1 NO 2.13 (0.15) 0.000
Post-translational modification, protein turnover, chaperone functions
Osmotically inducible protein C AIS04957.1 NO 3.16 (1.14) 0.029
Replication and repair
DNA repair protein AIS04967.1 YES 3.87 (1.19) 0.033
DNA polymerase I AIS05372.1 NO 0.31 (0.34) 0.038
Secondary metabolites: biosynthesis, transport and catabolism
mRNA 3′-end processing factor AIS06680.1 NO 0.10 (0.19) 0.027
Transcription
DNA-directed RNA polymerase subunit beta’ AIS05081.1 NO 2.86 (0.42) 0.025
Transcription elongation factor NusA AIS05126.1 NO 3.53 (0.94) 0.036
Transcription termination factor Rho AIS05365.1 NO 3.60 (1.54) 0.025
DNA-binding protein AIS07045.1 NO 9.73 (6.82) 0.029
DNA-directed RNA polymerase subunit alpha AIS07896.1 NO 3.28 (0.46) 0.001
Translation
Tyrosyl-tRNA synthetase AIS04798.1 NO 3.37 (0.97) 0.009
23S rRNA methyltransferase AIS05117.1 NO 3.37 (4.80) 0.037
Alanyl-tRNA synthetase AIS05862.1 NO 3.05 (1.16) 0.004
30S ribosomal protein S20 AIS06347.1 YES 3.77 (2.31) 0.026
Ribosome-recycling factor AIS06861.1 NO 3.91 (1.42) 0.045
Peptide chain release factor 1 AIS07012.1 NO 0.34 (0.27) 0.021
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Table 2 Differentially expressed proteins under ex vivo conditions in macrophage model (Continued)
30S ribosomal protein S6 AIS07031.1 NO 6.92 (1.66) 0.000
30S ribosomal protein S18 AIS07032.1 NO 22.70 (16.56) 0.028
50S ribosomal protein L9 AIS07033.1 NO 8.17 (3.02) 0.002
30S ribosomal protein S2 AIS07184.1 NO 3.87 (1.07) 0.040
Translation
Tryptophanyl-tRNA synthetase AIS07557.1 NO 8.09 (4.24) 0.023
50S ribosomal protein L27 AIS07585.1 YES 10.28 (8.73) 0.027
Aspartyl-tRNA synthetase AIS07787.1 NO 5.92 (1.79) 0.038
30S ribosomal protein S9 AIS07845.1 YES 5.86 (1.38) 0.009
50S ribosomal protein L17 AIS07895.1 YES 9.64 (4.81) 0.003
30S ribosomal protein S4 AIS07897.1 NO 13.30 (3.19) 0.010
50S ribosomal protein L15 AIS07902.1 NO 5.92 (1.17) 0.000
30S ribosomal protein S5 AIS07904.1 YES 4.61 (5.00) 0.003
50S ribosomal protein L18 AIS07905.1 YES 9.04 (10.58) 0.033
50S ribosomal protein L6 AIS07906.1 YES 7.59 (1.58) 0.037
30S ribosomal protein S8 AIS07907.1 YES 10.76 (2.98) 0.011
50S ribosomal protein L5 AIS07909.1 NO 7.73 (2.20) 0.000
50S ribosomal protein L24 AIS07910.1 YES 4.25 (0.70) 0.038
50S ribosomal protein L14 AIS07911.1 NO 11.07 (12.57) 0.002
30S ribosomal protein S17 AIS07912.1 NO 12.36 (3.91) 0.048
50S ribosomal protein L16 AIS07914.1 YES 29.11 (22.95) 0.038
30S ribosomal protein S3 AIS07915.1 NO 6.73 (3.82) 0.026
50S ribosomal protein L22 AIS07916.1 NO 1.89 (0.85) 0.035
50S ribosomal protein L2 AIS07918.1 YES 7.87 (3.98) 0.038
50S ribosomal protein L23 AIS07919.1 YES 4.45 (1.04) 0.018
50S ribosomal protein L4 AIS07920.1 NO 14.45 (7.02) 0.002
Translation
50S ribosomal protein L3 AIS07921.1 NO 6.25 (1.29) 0.042
The protein profiles produced by A. baumannii grown in the presence of macrophages were performed using iTRAQ reagents and LC-MS/MS. Differential expression was
defined by a relative abundance ratio >1.5 and <0.5
aSecretion prediction are based on (SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/), Phobius (http://phobius.sbc.su.se/), PrediSi (http://www.predisi.de/),
TatP 1.0 (www.cbs.dtu.dk/services/TatP-1.0), Tatfind 1.4 (http://signalfind.org/tatfind.html), SecretomeP 2.0 (www.cbs.dtu.dk/services/SecretomeP), TMHMM
(http://www.cbs.dtu.dk/services/TMHMM/), DAS-TMfilter (http://www.enzim.hu/DAS/DAS.html), LipoP 1.0 (www.cbs.dtu.dk/services/LipoP), DOLOP (http://
www.mrc-lmb.cam.ac.uk/genomes/dolop/), and LIPO (http://services.cbu.uib.no/tools/lipo))
bAverage relative protein expression level ratio in sample and control, with the standard deviation in parentheses, quantified by Protein Pilot 4.0 software (ABSciex).
cDetermined by Student’s t test. Values of less than 0.05 are considered significant
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RT-PCR analysis was applied to 6 genes coding for dif-
ferentially expressed proteins to confirm the findings of
the proteomic analysis. Expression of most, but not all,
of these genes paralleled expression of the corresponding
proteins revealed by proteomic analysis. Four (NfuA-like,
YjjK, CsuC and OmpW) of the six selected genes were
over-expressed at the transcriptional level in the sample
relative to the control which is consistent with the re-
sults of protein expression. However, there was a slight
inconsistency between the translational and transcrip-
tional levels of OmpA and ClpX. Expression of OmpA
and ClpX mRNA revealed similar patterns in the samplerelative to the control, despite the increased levels of the
respective mRNAs (Fig. 3, Table 1).
Macrophage model
RT-PCR analysis of 7 genes coding for differentially
expressed proteins was performed to confirm the re-
sults of the proteomic analysis. Expression of most,
but not all, of the genes paralleled the expression of
the corresponding proteins revealed by proteomic ana-
lysis. Five (DNA repair, PaaA, PpiA,YjjK and OmpW)
of the seven selected genes were over-expressed at the
transcriptional level in the sample, relative to the con-











Fig. 1 Venn diagram showing the number and relationship
between A. baumannii proteins that were differentially expressed
in comparison of 2 ex vivo models. Circles represent the set of
over-expressed proteins (red) and under-expressed proteins (dark
blue) in the macrophage model and the set of over-expressed
proteins (yellow) and under-expressed proteins (light blue) in the
BALF model. The number of proteins differentially expressed is
indicated in each set or subset
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between the translational and transcriptional levels of
OmpA and an inconsistency between the translational
and transcriptional levels of CsuC. The mRNA expres-
sion of OmpA revealed similar patterns in the sample,
relative to the control, despite the increased levels of
the respective mRNAs. The mRNA expression of
CsuC was 1.6 times higher and the protein abundance
was more than six times lower in the sample than in
the control (Fig. 4, Table 2), probably because of post-
transcriptional regulation [33].
Comparison of the results obtained by iTRAQ labelling-
LC-MALDI/TOF and RT-PCR showed that the changes
observed in protein abundance between samples of both
ex vivo models and controls were also reflected in the
mRNA levels.
Discussion
The host activated response to Acinetobacter baumannii
is not well understood. Some studies have described
changes in A. baumannii gene expression under
in vivo-mimicking conditions. However, most of these
studies focused on transcriptional changes of one or a
few genes of interest, mostly under iron limiting con-
ditions [34–38]. A microarray study defined the ex-
pression properties of A. baumannii during growth inhuman serum and demonstrated significant over-
expression of iron acquisition systems, of genes associ-
ated with epithelial cell adherence, DNA uptake and
of numerous putative drug efflux pumps [39]. At the
protein level, comparative analysis of total lysate and
outer membrane fractions isolated from A. baumannii
cultured under iron-rich and iron-chelated conditions
led to identification of 58 modulated proteins [40].
There remains an alarmingly large gap in our know-
ledge of the pathogenesis and nature of A. baumannii
virulence. A better understanding of the adaptation of
A. baumannii to the host and its molecular pathogen-
esis is essential for the development of new thera-
peutic and diagnostic methods. Research studies that
address the A. baumannii proteome in vivo and the
proteome that is produced in the presence of fluid or
host cells are lacking. In contrast to the numerous
proteomic studies of A. baumannii cultivated in vitro
laboratory settings, only one microarray study has
been carried out ex vivo, and no ex vivo or in vivo
proteomic studies have been performed. This is be-
cause of technical limitations, which severely limit the
number of recovered bacteria, and the potential con-
tamination of sample preparations by host cell nucleic
acids or proteins.
To identify putative pathogenesis and virulence fac-
tors that mediate A. baumannii pathogenesis, we used
2 ex vivo models and a quantitative proteomics ap-
proach. We provide evidence that expression of 179 A.
baumannii proteins is affected by the host. Comparison
of both models showed that 83 % of the proteins
detected were grouped in the same category in both models
(under-expressed, over-expressed and un-modulated) and
that most of the proteins were unmodulated, which indi-
cates that the host proteins may target and regulate a
specific small group of A. baumannii proteins. The modu-
lated proteins possess diverse functions (Fig. 2, Table 1 and
Table 2), which suggests a complex interaction between the
bacterium and the host. Thus, in the BALF model, 50 of
the proteins identified were over-expressed, whereas 61
were under-expressed. Some of these functional groups
are clearly over-expressed for functioning in cell wall/
membrane/envelope biogenesis, nucleotide metabolism
and transport and cell cycle control and mitosis. Other
important biological processes, such as pathogenesis
and virulence and translation, were mainly over-
expressed. However, other metabolic proteins involved
in, e.g., amino acid metabolism and lipid metabolism
were under-expressed. In the macrophage model, 76 of
the proteins identified were over-expressed, whereas
21 were under-expressed. Some of these functional
groups are clearly over-expressed for functioning in
translation, transcription and energy production and
conversion. Other important biological processes, such












Protein CsuC AIS07073.1 YES 2.19 (0.76) 0.003 0.16 (0.06) 0.004
Protein CsuA AIS07075.1 YES 1.87 (0.95) 0.036 0.31 (0.22) 0.040
Membrane protein (OmpA) AIS07737.1 YES 1.51 (0.65) 0.015 7.80 (2.78) 0.049
Oligopeptidase A AIS07885.1 NO 0.48 (0.11) 0.001 4.83 (0.88) 0.006
ABC transporter ATP-binding protein
(YjjK)
AIS08062.1 NO 1.74 (0.61) 0.038 2.33 (0.77) 0.046
Amino acid metabolism and transport
Aspartate aminotransferase AIS07065.1 NO 0.08 (0.07) 0.000 0.39 (0.18) 0.010
Carbohydrate metabolism and transport




AIS08199.1 NO 99.08 (0.00) 0.020 8.17 (3.95) 0.040
Coenzyme metabolism
3-Phosphoglycerate dehydrogenase AIS07996.1 NO 0.38 (0.09) 0.016 3.77 (0.88) 0.014
Energy production and conversion
Isocitrate dehydrogenase AIS07371.1 NO 0.29 (0.05) 0.004 4.57 (0.55) 0.002
Acetyl-CoA hydrolase AIS08069.1 NO 2.05 (0.67) 0.008 4.74 (1.68) 0.040
Unknown function
Hypothetical protein AIS05481.1 YES 0.07 (0.10) 0.013 0.17 (0.08) 0.000
DNA-binding protein AIS07086.1 YES 0.08 (0.07) 0.006 0.24 (0.17) 0.037
Glyoxalase AIS07740.1 YES 0.39 (0.45) 0.015 0.30 (0.23) 0.036
Inorganic ion transport and metabolism
Hydroperoxidase AIS06129.1 YES 0.26 (0.10) 0.000 0.35 (0.13) 0.008
Lipid metabolism
Short-chain dehydrogenase AIS06130.1 YES 0.04 (0.05) 0.040 0.10 (0.07) 0.032
Nucleotide metabolism and transport
Deoxyuridine 5′-triphosphate
nucleotidohydrolase
AIS05628.1 NO 4.45 (6.37) 0.039 0.28 (0.32) 0.032
Transcription
DNA-directed RNA polymerase subunit
beta’
AIS05081.1 NO 0.10 (0.04) 0.000 2.86 (0.42) 0.025
Translation
30S ribosomal protein S6 AIS07031.1 NO 3.56 (0.80) 0.004 6.92 (1.66) 0.000
50S ribosomal protein L9 AIS07033.1 NO 4.70 (2.06) 0.000 8.17 (3.02) 0.002
30S ribosomal protein S9 AIS07845.1 YES 6.19 (2.19) 0.005 5.86 (1.38) 0.009
50S ribosomal protein L17 AIS07895.1 YES 15.14 (7.44) 0.025 9.64 (4.81) 0.003
50S ribosomal protein L15 AIS07902.1 NO 5.06 (1.54) 0.000 5.92 (1.17) 0.000
50S ribosomal protein L6 AIS07906.1 YES 5.35 (2.12) 0.000 7.59 (1.58) 0.037
30S ribosomal protein S8 AIS07907.1 YES 7.52 (1.56) 0.007 10.76 (2.98) 0.011
50S ribosomal protein L5 AIS07909.1 NO 7.18 (2.38) 0.000 7.73 (2.20) 0.000
50S ribosomal protein L14 AIS07911.1 NO 5.20 (1.87) 0.002 11.07 (12.57) 0.002
50S ribosomal protein L22 AIS07916.1 NO 2.03 (0.76) 0.012 1.89 (0.85) 0.035
50S ribosomal protein L23 AIS07919.1 YES 1.77 (0.58) 0.043 4.45 (1.04) 0.018
The protein profiles produced by A. baumannii grown in modified BALF and in the presence of macrophages were performed using iTRAQ reagents and LC-MS/
MS. Differential expression was defined by a relative abundance ratio >1.5 and <0.5
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aSecretion prediction are based on (SignalP 4.1 (http://www.cbs.dtu.dk/services/SignalP/), Phobius (http://phobius.sbc.su.se/), PrediSi (http://www.predisi.de/),
TatP 1.0 (www.cbs.dtu.dk/services/TatP-1.0), Tatfind 1.4 (http://signalfind.org/tatfind.html), SecretomeP 2.0 (www.cbs.dtu.dk/services/SecretomeP), TMHMM
(http://www.cbs.dtu.dk/services/TMHMM/), DAS-TMfilter (http://www.enzim.hu/DAS/DAS.html), LipoP 1.0 (www.cbs.dtu.dk/services/LipoP), DOLOP (http://
www.mrc-lmb.cam.ac.uk/genomes/dolop/), and LIPO (http://services.cbu.uib.no/tools/lipo))
bAverage relative protein expression level ratio in sample and control, with the standard deviation in parentheses, quantified by Protein Pilot 4.0 software (ABSciex).
cDetermined by Student’s t test. Values of less than 0.05 are considered significant
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and transport, were mainly over-expressed. However,
other functional groups involved in lipid metabolism were
under-expressed. Although both models yielded generally
similar results, some differences in the findings are not
surprising, for the following reasons. First, different ro-
dents species were used as hosts. Moreover, some of the
major influencing factors identified in the BALF model
include nutritional differences between samples (LB
broth+lipids, nucleic acids, peptides and proteins) and
controls (LB) and stress resulting from host inflamma-
tory response (proteins important for immunity and
host defence functions, such as surfactant protein A and
surfactant protein D). However, in the macrophage model,0
Pathogenesis and Virulence
amino acid metabolism and transport
cell wall/membrane/envelope biogenesis
defense mechanisms (cellular processes and signaling)
function unknown
Inorganic ion transport and metabolism
lipid metabolism
nucleotide metabolism and transport
translation
replication and repair
secondary metabolites biosynthesis, transport and catabolism
cell cycle control and mitosis
post-translational modification, protein turnover, chaperone functions
transcription
carbohydrate metabolism and transport
energy production and conversion
coenzyme metabolism
general functional prediction only (typically, prediction of biochemical activity)












Fig. 2 Distribution of differentially expressed proteins in A. baumannii follo
stacked bar chart shows the number of over-expressed proteins (red) and u
the number of over-expressed proteins (yellow) and under-expressed protethese factors may compete with macrophages for available
nutrients and stress resulting from interaction with a sin-
gle host cell type.
Proteomic comparison of the levels of protein ex-
pression in the models revealed that 82 proteins were
only modulated by BALF, 68 proteins were only modu-
lated by macrophages and 29 proteins were modulated
by both. Of these 29 proteins, 15 were over-expressed,
6 proteins were under-expressed and 8 proteins were
opposite (Fig. 1). Interestingly, 50.0 % of opposite proteins
were associated with metabolism (phosphoglyceromutase,
3-phosphoglycerate dehydrogenase, isocitrate dehydro-
genase and deoxyuridine 5′-triphosphate nucleotidohy-
drolase). This is probably due to differences in the5 10 15 20 25 30
Number of proteins
wing ex vivo incubation according to functional categories. The
nder-expressed proteins (dark blue) in the macrophage model and




























Fig. 3 RT-PCR analysis of different genes coding for differentially expressed proteins in controls and samples (BALF model). All expression results
were normalized relative to RpoB by the 2−ΔΔCt method. For all genes, relative mRNA expression is presented as a fold-change value relative to
the control
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and to competition with macrophages for available nu-
trients in the macrophage model. Over-expressed
amino acid catabolism was also observed in the
macrophage model and under-expressed amino acid
catabolism in the BALF model (Table 3), indicating
that amino acids constitute a major source of nitrogen
for A. baumannii in the macrophage model. The avail-
ability of amino acids is probably also partly due to
uptake of oligopeptides. Thus, the oligopeptidase A
was over-expressed in the macrophage model and
under-expressed in the BALF model. Moreover, CsuC
and CsuA were over-expressed in the host cell-free
model (the BALF model) and under-expressed in
macrophage model, because these proteins are in-
volved in initial attachment to abiotic surfaces but not






























Fig. 4 RT-PCR analysis of different genes coding for differentially expressed p
results were normalized relative to RpoB by the 2−ΔΔCt method. For all genes,
the controlNevertheless, the explanation is not as obvious in the
case of the modulation of DNA-directed RNA poly-
merase subunit beta’.
In the macrophage model, 3 predicted outer mem-
brane proteins were over-expressed (a DcaP-like protein,
a membrane protein and OmpA -iTRAQ ratio between
7.80 and 11.07). In the BALF model, 2 predicted outer
membrane proteins were over-expressed (OmpW family
protein and OmpA -iTRAQ ratio between 1.51 and
2.25). In the macrophage model, 21 predicted secreted
proteins were also over-expressed (average iTRAQ ratio
7.88) and 10 were under-expressed (average iTRAQ ratio
0.25). In the BALF model, 17 predicted secreted proteins
were over-expressed (average iTRAQ ratio 4.03) and 13
were under-expressed (average iTRAQ ratio 0.20). The
modifications that A. baumannii undergoes as a result
of host-induced stress include changes in membrane andCsuC Omp38 YjjK OmpW
enes
hage model
roteins in controls and samples (macrophage model). All expression
relative mRNA expression is presented as a fold-change value relative to
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the macrophage model than in the BALF model (host
cell-free model) probably due to pathogen-host cell in-
teractions. We conclude that the outer membrane and
secretome are changed by the host cells and host
secretome.
Interestingly, we found that the UDP-N-acetylmuramate-
L-alanine ligase (MurC) protein was strongly over-
expressed in both ex vivo models (iTRAQ ratio of 99.08 in
the BALF model, and iTRAQ ratio of 8.17 in macrophage
model). We also observed that UDP-N-acetylglucosamine
1-carboxyvinyl transferase (MurA) was over-expressed in
the BALF model, but not significantly over-expressed in
the macrophage model (p > 0.05). In peptidoglycan synthe-
sis, uridine-diphospho-N-acetylglucosamine is converted
via MurA and MurB to UDP–N-acetylmuramic acid, to
which alanine is added by MurC. These are essential steps
in cell wall biosynthesis in bacteria [41, 42]. Moreover,
MurA is required for full virulence in Listeria monocyto-
genes [43]. In this context, MurA has previously been sug-
gested as a potential drug target, and effective inhibitors
of this protein have been identified [44]. Detection of
MurC polypeptides in humans could provide a method
for diagnosis and/or prognosis of an infection. Levels of
MurC polypeptides could be determined using assay tech-
niques such as include antibody detection, ELISA assays,
antibody sandwich assays and Western Blot analysis.
Monoclonal antibodies against A. baumannii MurC simi-
lar to those generated by Zoeiby et al. could be used to de-
tect MurC polypeptides. Zoeiby et al. used purified P.
aeruginosa MurC protein to develop monoclonal anti-
bodies against MurC. Moreover, Zoeiby et al. suggested
that a specific inhibitor designed against P. aeruginosa
MurC may display universal activity against all bacteria
[45]. However, other authors have observed that C-1, a
competitive inhibitor of ATP binding to the MurC en-
zyme, was equally effective at inhibiting MurC from E.
coli, Klebsiella pneumoniae and Proteus mirabilis, but that
MurC enzymes from more distantly related Gram-
negative species such as Acinetobacter baylyi, Pseudo-
monas aeruginosa and Haemophilus influenzae were not
inhibited [46]. More recently, MurC enzymes from
Escherichia coli and Pseudomonas aeruginosa have been
found to be inhibited by a novel class of pyrazolopyrimi-
dines [47].
Putative virulence-associated factors
Several putative virulence factors were modulated in both
ex vivo models. Blast analysis (http://blast.ncbi.nlm.nih.gov/
Blast.cgi) [48, 49] revealed significant alignment between
the nucleotidyl transferase (AIS04894.1), which was found
to be over-expressed in the macrophage model (but not sig-
nificantly modulated (p > 0.05) in the BALF model) and
UTP-glucose-1-phosphate uridylyltransferase (GalU) (querycover 100 % and Evalue = 0.0). The GalU gene encodes for
production of UTP-glucose-1-phosphate uridyltransferase,
an enzyme that catalyzes the formation of UDP-glucose
and is known to have a key role in biosynthesis of cell-
envelope-associated carbohydrates (e.g. lipopolysaccharides
[LPS] and capsule) in a variety of bacterial species. In many
Gram-negative pathogens, mutations in GalU lead to atten-
uated virulence, mainly because of changes in LPS or
capsular structures. Formation of these polysaccharides is
critical to bacterial virulence because this enables the bac-
teria to evade attack by the host immune system. The GalU
gene has also been found to be important for pathogenesis
of e.g. Pseudomonas aeruginosa and Francisella tularensis
[50–54].
Bacteria and their hosts are involved in competition
for available iron. In the host, iron is sequestered by fer-
ritin, transferrin, haemoglobin, myoglobin, haptoglobin
and haemopexin, thus decreasing the availability of free
iron to concentrations below those needed for bacteria
to persist in the environment. Therefore, bacteria must
survive by competing with the host for iron through the
expression of iron acquisition systems. These systems
produce high affinity iron chelators known as sidero-
phores, which are secreted into the extracellular milieu
[55, 56]. Lipocalin-1 is secreted by the lingual glands,
sweat glands, prostate, and secretory glands of the tra-
cheobronchial tract, as well as by the nasal mucosa into
BALF, sweat, saliva, tear, sputum and nasal fluids.
Lipocalin-2, which is secreted by neutrophils, macro-
phages, dendritic cells and exocrine glands into trachea,
lung, sputum, BAL, stomach, small intestine, pancreas,
kidney, prostate, thymus and plasma, interferes with
siderophore-mediated iron-uptake. Lipocalin-1 binds to
different bacterial siderophores, including bacterial
catecholate-type (enterobactin) and hydroxamate-type
(ferricrocin) and mixed citrate-hydroxamates (aerobactin).
Lipocalin-2 binds to different bacterial siderophores, in-
cluding enterobactin-type bacterial siderophores and
carboxy-mycobactins. To defend themselves against the
host, some bacteria use countermeasures to subvert the
iron-withholding effects of Lipocalin-2. For example, Sal-
monella and Klebsiella spp. glycosylate enterobactin,
whereas M. tuberculosis modifies its carboxymycobactins.
Both mechanisms sterically impair the ability of Lipocalin-
2 to bind these siderophores [57–60]. NfuA-like has mul-
tiple functional roles related to iron-mediated stress.
NfuA-like is involved in intracellular iron metabolism and,
as demonstrated in an infection model, it also plays a role
in the virulence of A. baumannii by protecting infecting
bacteria from oxidative responses rather than providing
iron to bacteria grown under iron—limited conditions im-
posed by cultured human alveolar epithelial cells and G.
mellonella larvae [37]. In the present study, we observed
that in both models, proteins involved in biosynthesis of
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ulated (p > 0.05), probably because lipocalin-1 binds to
aerobactin. We also observed that one of the under-
expressed proteins (not significantly under-expressed
(p > 0.05) in the BALF model) is associated with biosyn-
thesis of the siderophore achromobactin (AIS06377.1).
This may be because although achromobactin is an
efficient hydroxycarboxylate siderophore at low pH
(pH < 5), achromobactin could not compete with stron-
ger siderophores such as catecholates at physiological
pH [59]. In both models, NfuA-like was also over-
expressed (although not significantly (p > 0.05), in the
macrophage model). Altogether, these results suggest a
third system for iron acquisition in A. baumannii strain
AbH12O-A2, but which is not identified by current bio-
informatic analysis. In a recent study, the structures of
six novel siderophores termed fimsbactin A-F have
been elucidated and the biosynthesis gene clusters for
fimsbactin production have been identified in A. baylyi
ADP1 and A. baumannii strains (ATCC 17978 and
6013150), although BLAST analysis showed that the
fimsbactin gene cluster is not present in A. baumannii
strain ABH12O-A2 (data not shown) [61].
In the macrophage model, we observed increased ex-
pression (not over-expressed in the BALF model:
iTRAQ ratio, 1.26) of the Tig factor in the ex vivo sam-
ples. De novo protein folding in Escherichia coli is
mainly orchestrated by the chaperone trigger factor and
by DnaK and GroEL. The ribosome-bound trigger fac-
tor is the first chaperone to interact cotranslationally
with nascent polypeptides. It has been suggested that a
trigger factor homologue in Streptococcus mutans is a
key regulator of stress tolerance, genetic competence
and biofilm formation, all of which are critical virulence
properties of this bacterium. In Listeria monocytogenes,
a trigger factor homologue is involved in the stress
response and associated pathogenicity [62–64].
We observed increased expression of the DnaK sup-
pressor protein, which was significant (p < 0.05) in the
BALF model, but not in the macrophage model. This
protein plays an important role in the virulence of
Salmonella and Escherichia coli [65].
In the BALF model, expression of the ClpX protein
increased (but was not significantly over-expressed
(p > 0.05) in the macrophage model). ClpX is required
for virulence, biofilm formation and intracellular repli-
cation in Staphylococcus aureus [66].
Initial attachment to abiotic surfaces is the first step for
colonization and subsequent biofilm formation on e.g.
ventilator tubing and catheters. In A. baumannii 19606,
the type I pili encoded by CsuA/BABCDE appears to be
involved in this process [67]. In our host cell-free model
(BALF model), the proteins OmpA (iTRAQ ratio = 1.51),
CsuA and CsuC were over-expressed, suggestingbiofilm activation by the host secretome that defends A.
baumannii against host on medical devices. Another crit-
ical step in the pathogenesis of A. baumannii is the ability
to adhere to eukaryotic cells, although the mechanisms of
adherence are different for abiotic and biotic surfaces. It
has been demonstrated that OmpA acts as a virulence fac-
tor in A. baumannii and has an important role in cell
death through both mitochondrial and nuclear targeting
[68]. The OmpA of A. baumannii 19606 also plays a par-
tial role in biofilm formation on plastic, but is essential for
attachment to biotic surfaces such as C. albicans and hu-
man alveolar epithelial cells. Interestingly, the absence of
these cell appendages also favours bacterial attachment
and invasion of epithelial cells. This may be due to greater
exposure of other unknown bacterial adhesion and biofilm
factors in the absence of pili [69]. In our macrophage
model, OmpA (iTRAQ ratio = 7.80) was over-expressed
and both CsuA and CsuC were under-expressed. Together
these results suggest that contact between A. baumannii
cells and macrophages may be an important factor deter-
mining underexpression of the CsuA/ BABCDE protein.
Elucidation of the complex interactions between A.
baumanniiand both abiotic and biotic surfaces is im-
portant for a better understanding of the pathobiology
of A. baumannii and also for identification of novel
targets for the development of new antimicrobial
strategies.
In the macrophage model, we observed increased ex-
pression of the PaaA protein in the ex vivo samples, but
we did not observe significant (p > 0.05) repression of
the PaaZ protein. In contrast, in the BALF model, we
observed repression of PaaZ protein but no modulation
(p > 0.05) of the PaaA protein. In the catabolism of phe-
nylacetic acid by some bacteria, PaaA encodes part of
the phenylacetic acid—coenzyme A ring hydroxylation
system, and opening of the aromatic ring may be per-
formed by PaaZ. In Burkholderia cenocepacia, PaaA in-
sertional mutants were attenuated for virulence and
interruption of increased virulence of PaaZ [70].
The success of a bacterial infection greatly depends on
the ability of the bacteria to use external nutrients.
Therefore, the proteolytic and lipolytic activities of
extracellular proteins may play key roles in the establish-
ment of A. baumannii infection [71]. In general, in the
macrophage model, proteins with proteolytic activity
were over-expressed, and in the BALF model, this type
of protein was under-expressed. This may be due to con-
tinuous production of host proteins in the macrophage
model but not in the BALF model as well as to over-
expressed amino acid metabolism in the macrophage
model and under-expressed amino acid metabolism in
the BALF model.
We identified a cyclophilin (PPIase) (AIS06968.1),
which was over-expressed in the macrophage model and
Méndez et al. BMC Genomics  (2015) 16:422 Page 16 of 21not modulated in the BALF model. It has been estab-
lished that PPIases may play a role during bacterial sur-
vival against macrophage attack, and it has been
suggested that PPIases may act as virulence factors by
interacting with some proteins from the host cell mem-
brane, thus helping render the host cell more susceptible
to penetration via conformational changes through cis-
trans isomerization of peptidyl-prolyl bonds [72, 73].
These types of proteins have been reported to affect the
phagocytosis of Streptococcus pneumoniae by macro-
phages [74].
In both models, the uncharacterized ABC trans-
porter ATP-binding protein YjjK was over-expressed.
The precise role of YjjK, encoding a putative ATP
binding protein of an ABC transporter, is not yet
known. However, YjjK is required for the entry and
survival of Porphyromonas gingivalis in gingival epi-
thelial cells [75]. It has also been suggested that YjjK is
involved in Francisella tularensis virulence [76].
Eighteen genes have been identified in A. baumannii
as being involved in growth on human ascites and
shown to be essential for growth and survival during in-
fection [77]. In the present study, we found 53 % of
these essential proteins: 4 of these were over-expressed
(OmpF, RpmA, CarA and PyrC), 4 were un-modulated
(AroA, AroC, RstA and SecE) and AceE was under-
expressed. The present findings are only partly consist-
ent with those of the aforementioned study [77] as SpsC
is not contained in the AbH12O-A2 genome and we did
not detect8 of the proteins. However, these differences
may be due to the undetected proteins occurring in
amounts below the detection/identification level or to
differences in the host microenvironment.
When A. baumannii infects the host airway, it is
present in multiple locations, including in the intersti-
tium between cells, embedded in mucus in the lumen,
inside and adhering to macrophages and epithelial cells.
Therefore, A. baumannii must adapt to multiple micro-
environments and may express different proteins, de-
pending on the microenvironment. We examined 2
ex vivo models of infection: a host cell-free model in
which A. baumannii interacts with soluble host compo-
nents present inside the infected lung, and an immune
system cells model, in which A. baumannii interacts
with macrophages. One limitation of the study is that we
only simulated some conditions in the host airways and
A. baumannii is present in many other microenviron-
ments. Caution must therefore be used in extrapolating
results of the present study to the human disease be-
cause A. baumannii populations that colonize the hu-
man airways are probably a mixture of A. baumannii
from different microenvironments.
The AbH12O-A2 strain yielded over-expressed ‘hypo-
thetical proteins’. Induced expression of hypotheticalproteins strongly indicates that A. baumannii generates
host resistance by unknown mechanisms. These genes
are obvious candidates for subsequent functional
characterization and for research aimed at determining
their function within infection processes.
Conclusions
This study is the first comprehensive overview of the
ex vivo proteome of the multidrug resistant microbial
pathogen A. baumannii and provides some insight into
the potential role of putative virulence proteins in vivo.
The ex vivo behaviour of A. baumannii was compared,
for the first time, under different infection condition-
s—in BALF and in the presence of macrophages—as well
as under in vitro conditions. A rapid enrichment tech-
nique was successfully used, together with MS/MS ana-
lysis, to characterize the ex vivo proteome of A.
baumannii and showed that the proteome is signifi-
cantly different from that of bacteria cultured in vitro.
The changes in the proteome observed for the strain A.
baumannii AbH12O-A2 indicate a response to stress
resulting from interaction with host and modification of
cell wall synthesis. We identified 2 over-expressed
virulence-associated proteins with >15 peptides/protein
in both ex vivo models (OmpA and an uncharacterized
ABC transporter ATP-binding protein YjjK), which
appear to be essential for pathogenesis and virulence in
the airways. Overall, the data suggest that A. baumannii
can use a variety of virulence mechanisms that enable it
to adapt to and survive in vastly divergent environments.
These data are helpful for elucidating the molecular
mechanisms associated with the interaction between A.
baumannii and host and represent an important step
towards identification of diagnostic biomarkers, novel
drug targets and potential vaccine candidates in the fight
against pneumonia caused by A. baumannii.
Methods
Bacterial strain
A highly invasive multidrug-resistant (including carba-
penems) Acinetobacter baumannii clone (AbH12O-A2),
which infected more than 300 patients in the 12 de
Octubre Hospital (Madrid, Spain) was used in this study.
The annotated sequence for AbH12O-A2 [GenBank
CP009534.1] is available at the National Center for Bio-
technology Information (NCBI) [78].
Rat model of pneumonia and BALF (bronchoalveolar
lavage fluid)
Male Wistar rats (INIBIC, A Coruña, Spain) of about
350 g weight were used in the experiment. Antibiotic-
free pelleted food and water were provided ad libitum
during the assay. The experiment was approved by the
Ethics Committee for Animal Experimentation of A
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toneally with sodium thiopental and were inoculated
intratracheally under direct vision with a bacterial sus-
pension, which was prepared as follows: bacteria were
grown at 37 °C in LB until an optical density of 0.7 at
600 nm, washed with sterile saline solution and mixed
1:1 with a saline solution of porcine mucin at 10 % (wt/
vol). The final inoculum was about 3 × 108 CFUs/rat. At
21 h after inoculation, animals were euthanized by intra-
peritoneal injection of an overdose of sodium thiopental.
The lungs were washed twice with about 45 ml normal
saline (0.9 % NaCl). The concentrations of the original
bacterial suspensions and of the BALF were determined
by the plate count method. The BALF from three ani-
mals was centrifuged (3000 × g, 30 min at 4 °C) to
remove cells, and the supernatant was filtered through a
0.22 μm membrane (low protein binding Millex-GP
polyethersulfone membrane (Millipore, Bedford, U.S.A.))
to remove residual bacteria. Absence of viable bacteria
was confirmed by culture on Mueller Hinton (MH) agar
plates. BALF was stored at −70 °C for a maximum of
3 months until use.
Histopathology
Paraformaldehyde-fixed lung tissue was embedded in
paraffin, sectioned and stained with hematoxylin and
eosin. Two to four sections from each lung of infected
rats were examined.
Incubation of A. baumannii in rat BALF
Acinetobacter baumannii strain AbH12O-A2 was
streaked on MH nutrient agar. A single colony was then
inoculated in 5 mL LB and grown overnight at 37 °C
with vigorous shaking. 100 mL of LB (10 g/L tryptone +
5 g/L yeast extract dissolved in saline solution instead of
water) and 100 ml of modified LB (40 g/L tryptone +
20 g/L yeast extract dissolved in saline solution instead
of water + 75 % (v/v) BALF as a physiologically relevant
source of host proteins to simulate conditions in the
respiratory tract) were inoculated with a 1:100 dilution
of the overnight culture and grown simultaneously for
21 h at 37 °C and 5 % CO2 without shaking. Three inde-
pendent biological replicates of each culture were pre-
pared but only 2 were used for the ITRAQ. Cells
(OD600 nm = 1.0-1.4) were harvested by centrifugation
at 2800 × g for 20 minutes at 4 °C, washed twice by sus-
pending in cold 0.9 % NaCl and centrifuged again under
the same conditions. The pellets were frozen and stored
at −70 °C until needed.
Macrophage infection with A. baumannii
Acinetobacter baumannii strain AbH12O-A2 was
streaked on MH nutrient agar. A single colony was then
inoculated in 5 mL LB and grown overnight at 37 °Cwith vigorous shaking. The overnight culture was har-
vested, washed once and resuspended in tissue culture
medium: DMEM with glucose and L-glutamine (4.5 g/
L dextrose + 3.7 g/L NaHCO3 + 0.015 g/L phenol red
+ 0.110 g/L sodium pyruvate + 0.200 g/L CaCl2 +
0.100 mg/L Fe(NO3)3.9H2O + 0.098 g/L MgSO4 +
0.400 g/L KCl + 6.400 g/L NaCl + 0.007 g/L i-Inositol
+ 0.109 g/L NaH2PO4 + 15 amino acids and vitamins
(BioWhittaker Lonza, Verviers, Belgium)) supple-
mented with 10 % fetal bovine serum and 1 % penicil-
lin/streptomycin. The concentration of bacterial cells
was then determined.
To mimic host microbe interactions involving phago-
cytic immune system cells the RAW 264.7 macrophage-
like cell line was plated in cell culture flasks at 3 × 107
cells/flask and incubated overnight at 37 °C with 5 %
CO2. Macrophage cells were washed twice with 20 ml/
flask of 0.9 % NaCl. The tissue culture medium was then
added to each flask, and 1 mL of the A. baumannii in
the tissue culture medium was added to each flask with
a multiplicity of infection of 3 (i.e. 3 times more bacterial
cells than macrophages were used). To increase the up-
take of A. baumannii and synchronize infection, flasks
were centrifuged at 250 × g for 5 min at room
temperature and then incubated at 37 °C with 5 % CO2
for 21 h without shaking. Three independent biological
replicates of each culture were prepared but only 2 were
used for the ITRAQ. The sample was harvested 21 h
post infection. Extracellular bacteria were isolated from
infected macrophage cultures. To isolate extracellular
bacteria, infected macrophage cultures were washed
three times with Hank’s buffered salt solution to remove
any bacteria that were not inside adherent cells. The har-
vested sample and the wash solutions were centrifuged
(500 × g for 2 min at 4 °C to pellet any nonadherent
macrophage cells) and the supernatants were combined.
The supernatant was centrifuged (1500 × g for 20 min at
4 °C) to pellet the bacteria. The pellet was resuspended
in phosphate-buffered saline (PBS) and filtered through
a Transwell filter membrane system (3.0-μm pore size;
BD Falcon, Erembodegem, Belgium). Macrophage cells
were very scarce. Bacteria then were washed twice by
suspending them in cold PBS and centrifuging (2800 × g
for 20 minutes at 4 °C). The pellets were frozen and
stored at −70 °C until needed. Control A. baumannii
cells were collected, washed and treated in the same way
as above but in the absence of macrophages.
Protein extraction
The resultant pellet was resuspended in disintegration
buffer (7.8 g/L NaH2PO4, 7.1 g/L Na2HPO4, 0.247 g/L
MgSO4.7H2O) + protease inhibitor mix (GE Healthcare,
Piscataway, USA) + nuclease mix (GE Healthcare,
Piscataway, USA) and sonicated on ice for 3 periods of
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gation at 1500 × g at 4 °C. The supernatant was centri-
fuged for at least 30 min at 4 °C and 4500 × g before
being clarified through a 0.22 μm membrane (low pro-
tein binding Millex-GP polyethersulfone membrane
from Millipore, Bedford, U.S.A.) to remove the cell
debris. Finally, the extract was processed with a 2-DE
Cleanup Kit (GE Healthcare, Piscataway, USA), follow-
ing the manufacturer’s instructions. The concentration
of protein was measured using the Bio-Rad protein
assay (Bio-Rad, Munich, Germany).iTRAQ labelling and LC-MALDI/TOF analysis
Labelling, 2-D liquid chromatography and MALDI-
TOF/TOF MS analysis of the samples were performed
as previously described [79], and stage tips were used
for peptide desalting. Briefly, 30 μg of protein from
each condition was reduced, cysteine was blocked,
digested with trypsin and labelled with respective iso-
baric tags using iTRAQ reagent Multiplex kit (AB Sciex
Ltd., Foster City, CA), according to the manufacturer’s
protocol. The sample labelling was as follows: iTRAQ
tags 114: control BALF model; iTRAQ tags 115: sample
BALF model; iTRAQ tags 116: control macrophage
model; iTRAQ tags 117: sample macrophage model. In
the first dimension, peptides were fractionated by basic
reversed-phase chromatography in a 1200 HPLC sys-
tem (Agilent) and were collected using a Gilson
FC203B fraction collector (Gilson, Middleton, WI). The
collected peptide fractions were desalted with the aid of
home made stage tips and separated by reversed-phase
chromatography at acid pH in a nanoLC system
(Tempo, ABSciex, Foster City, CA). The peptides were
desalted and concentrated in a trapping column (0.5 ×
2 mm, Michrom Bioresources, Auburn, CA) at a flow
rate of 15 μL/min for 15 min and loaded onto a C18
column (Integrafit C18, Proteopep II, 75 μm i.d., 15 cm,
5 μm, 300 Å; New Objective, Woburn, MA). Peptides
were eluted at a flow rate of 0.35 μL/min during a 2 h
linear gradient from 2 to 40 % B (mobile phase A: 0.1 %
trifluoroacetic acid, 2 % acetonitrile; mobile phase B:
0.1 % trifluoroacetic acid, 95 % acetonitrile), mixed with
α-cyano matrix (4 mg/mL at a flow rate of 1.2 μL/ min),
automatically deposited on a MALDI plate using a
MALDI spotter (SunCollect, Sunchrome, Friedrichsdorf,
Germany) and were finally analyzed in a 4800 TOF/TOF
system (ABSciex, Foster City, CA). The chromatograms
were composed by 480 spots, each comprising a 15 s
deposition. Explorer v.4.2 (ABSciex, Foster City, CA)
software (series 4000) was used to generate both the
spectra and peak list. Plate model and default calibra-
tion of the MALDI plate were performed at a laser volt-
age of 3400 kV and 1000 shots/spectrum. Samples wereautomatically analyzed in MS mode at a laser voltage of
3800 kV and 1500 shots/spectrum.
Automated precursor selection was carried out by a
Jobwide interpretation method, which selects up to 12
precursors per fraction. The lower threshold of signal to
noise (50) and trypsin autolytic peptides and other back-
ground ions were excluded. The laser voltage was
4800 kV, and 2000 shots/spectrum were acquired using
a medium-range CID collision energy.
LC-MALDI-TOF/TOF data were analyzed using Pro-
tein Pilot 4.0 software (ABSciex, Foster City, CA) as the
search engine for protein identification. Protein Pilot
search parameters were as follows: Cys-alkylation, iodoa-
cetamide; iTRAQ 4plex quantitation mode, biological
modifications; digestion with trypsin; All searches were
performed against the non-redundant NCBI library
(http://ncbi.nlm.nih.gov) database comprising annotated
proteins of Acinetobacter baumannii AbH12O-A2 and
pMMA2 plasmid. The search effort comprised thorough
ID and detection protein threshold of unused ProtScore
(Conf > 1.3 (95.0 %)). The scoring model was defined
by the Paragon algorithm. Bias and background
correction were applied to correct experimental differ-
ences in total amount of protein used in the experi-
ment and label interference, respectively. Proteins
showing sample/control protein expression ratios
below 0.5 or above 1.5 (p < 0.05) were considered to
be respectively under- or over-expressed and were
selected for further analysis.Purity of the starting material
The MS analysis of A. baumannii in BALF model and
in macrophage model did not reveal any of the most
abundant BALF proteins (serum albumin, IgG, IgA,
transferrin, haptoglobin and antitrypsin) [80], nor the
most abundant protein component of alveolar surfactant
(surfactant protein A) [81], nor the very abundant en-
zymes phosphoglycerate kinase (cytosol of macrophages)
and metallopeptidase 9 (macrophage membranes) [82].
We therefore, concluded that the starting material for
the A. baumannii proteome analysis was not (or only
minimally) contaminated with host material. This was
not surprising because BALF proteins sediment at
much higher centrifugation speeds than bacteria and
because we could barely see nonadherent macrophage
cells (see section “Macrophage infection with A.
baumannii”).Bioinformatics
Protein function was determined by http://www.ncbi.
nlm.nih.gov.
HHomp, http://toolkit.tuebingen.mpg.de/hhomp# was
used for the prediction of outer membrane proteins.
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a combination of algorithms (SignalP 4.1 (http://www.
cbs.dtu.dk/services/SignalP/), Phobius (http://phobius.sbc
.su.se/), PrediSi (http://www.predisi.de/), TatP 1.0 (www
.cbs.dtu.dk/services/TatP-1.0), Tatfind 1.4 (http://signalfin-
d.org/tatfind.html), SecretomeP 2.0 (www.cbs.dtu.dk/ser-
vices/SecretomeP), TMHMM (http://www.cbs.dtu.dk/ser
vices/TMHMM/), DAS-TMfilter (http://www.enzim.hu/D
AS/DAS.html), LipoP 1.0 (www.cbs.dtu.dk/services/LipoP),
DOLOP (http://www.mrc-lmb.cam.ac.uk/genomes/dolop/),
and LIPO (http://services.cbu.uib.no/tools/lipo)). [see
Additional file 3].
RNA extraction and RT-PCR
Total RNA was extracted using the High Pure RNA iso-
lation kit (Roche, Mannheim, Germany), according to
the manufacturer’s instructions. PCR without reverse
transcriptase confirmed the absence of DNA. Templates
of 100 ng of total RNA were used in the target gene
studies. Real-time PCR analysis of gene expression was
performed in duplicate with specific internal oligo-
nucleotide primers and the TaqMan probe (Universal
ProbeLibrary-UPL, Roche, Mannheim, Germany). All
primers and UPL probes used in the RT-PCR study are
shown in Additional file 4.
Availability of supporting data
The proteomics data sets supporting the results of this
article are included within the article and its Additional
file 5.
Additional files
Additional file 1: Workflow of the proteomic experiment. Strategy
used to recover and identify the proteins of A. baumannii in 2 ex vivo
models for proteomic analysis.
Additional file 2: Histopathology shows signs of consolidated
pneumonia in infected animals. A), C) and E) representative low (×4) -
and B), D) and F) high (×40)-power histological sections of lungs from
three rats infected with A. baumannii for 21 h. A – F haematoxylin and
eosin staining.
Additional file 3: Prediction of exoproteins. This figure indicates
the sequential use of different algorithms into a majority vote
decision. Coding sequences were scanned for the presence of signal
peptide specific to Sec pathway and Tat pathway. Coding sequences
exhibiting no signal peptide were screened as potential nonclassically
secreted proteins using SecretomeP 2.0. Proteins predicted as secreted
were then asked for the presence of cell-envelope retention domain and
erased from the output in positive case. Y, yes; N, no.
Additional file 4: RT-PCR analysis of different genes. Primers and
Univesal ProbeLibrary (UPL, Roche) probes used in this study.
Additional file 5: Protein identification data. Excel workbook
containing 2 worksheets with the complete report for the proteins in
both models exported from Protein Pilot software.
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